Citations

Clear

13603 citation(s) found for "_, _".

Medicaid Reimbursement for Common Orthopaedic Foot and Ankle Procedures Is Highly Inconsistent Among States, Ranging from 37% to 324% of Medicare Reimbursement
Adám, H , Moore, M. Lane , Beckett, Nathan , Schuyver, Paul R. Van, Haglin, Jack M. , Brinkman, Joseph C. , Adam, Henderson , Beckett, Nathan C, Moore, M Lane , Schuyver, Paul Van , Patel, Karan A.

Mayo Clinic

Foot & Ankle Orthopaedics | April 15, 2025 | Volume: 10 | Issue: 2 | Pages: No page available

10.1177/24730114251330302 | PMID 40297401 Get It

Background: Medicaid reimbursement to physicians is often perceived to be lower than Medicare, but little is known about orthopaedic foot and ankle reimbursement. This study sought to compare Medicare and Medicaid reimbursement for the 20 most common foot and ankle procedures. Methods: Medicare reimbursement rates for common foot and ankle codes were obtained from the online Centers for Medicare & Medicaid fee schedule, while Medicaid rates were found from individual state fee schedule websites. Medicaid rates were compared by state and pooled to obtain national differences. The Medicare Wage Index was used to adjust Medicaid rates by state wages to ensure a more accurate comparison. Variability between states was measured using state percentages of Medicare and coefficient of variation values. Results: Medicaid reimbursed physicians higher than Medicare in 31 states overall, with average reimbursement ranging from 37% to 324% of Medicare. Nationally, Medicaid reimbursed 8.8% higher than Medicare, but Medicare reimbursed 3.7% higher when adjusted for the Medicare Wage Index. The Current Procedural Terminology ( CPT ) codes with the highest ratio of Medicaid to Medicare reimbursement were CPT 28002 for incision and drainage of the foot (176.6%) and CPT 28820 for toe amputation (167.6%). Five codes had lower relative Medicaid reimbursement on average: CPT 27687 for repair procedures on the leg and ankle joint, CPT 28810 for amputation procedures on the foot and toes, CPT 28010 for toe tenotomy, CPT 28005 for incision procedures on the foot and toes, and CPT 28470 for closed treatment of a metatarsal fracture. The coefficient of variation values ranged from 0.34 to 0.84 in the Medicaid group and 0.40 to 0.78 in the adjusted group, indicating high variability between states and between procedures. Conclusion: Medicaid reimbursement is highly inconsistent between states, ranging from 37% to 324% of Medicare. Medicaid reimbursed more than Medicare overall, which is in contrast with most published findings that tend to show higher reimbursement for Medicare when compared to Medicaid. When adjusting for wage differences between states, Medicare reimbursed slightly higher than Medicaid. Level of Evidence: Level IV, economic analysis.
Predicting Remission in Antiphospholipase A2 Receptor Antibody-Associated Membranous Nephropathy
Barbour, Sean J. , Ronco, Pierre, Praga, Manuel , Fervenza, Fernando C. , Induruwage, Dilshani , Zhu, Bingyue , Fernández‐Juárez, Gema , Caravaca‐Fontán, Fernando , Cattran, Daniel C., investigators, For the GEMRITUX, MENTOR and STARMEN, Fernández-Juárez, Gema , Caravaca-Fontán, Fernando , Fervenza, Fernando C , Ronco, Pierre Marie , Dêbiec, Hanna , investigators, For the GEMRITUX, MENTOR and STARMEN

Mayo Clinic

Clinical Journal of the American Society of Nephrology | April 14, 2025 | Volume: 20 | Issue: 6 | Pages: 854-865

10.2215/cjn.0000000694 | PMID 40228233 Get It

Key Points In phospholipase A2 receptor-membranous nephropathy, clinical variables and antibody levels over 3 or 6 months of treatment were predictors of remission at 1 year. Prediction models at 3 and 6 months had similar performance predicting remission, with the 3-month model allowing for earlier assessment of response. The 3-month and 6-month prediction models could be applied in those treated with supportive therapy, rituximab, calcineurin inhibitors, or cyclophosphamide. Background In patients with antiphospholipase A2 receptor antibody–associated membranous nephropathy, there is currently no accepted method to predict an individual's probability of remission after treatment with immunosuppression or supportive therapy using changes in antibody levels and clinical variables during the first 3–6 months of therapy. Methods Using a cohort of 187 patients from the Glomérulopathie extramembraneuse rituximab, Membranous Nephropathy Trial of Rituximab, and Sequential Treatment with Tacrolimus and Rituximab Versus Alternating Corticosteroids and Cyclophosphamide in primary Membranous Nephropathy clinical trials with antibody levels at baseline ≥14 RU/ml, we derived logistic regression models to predict proteinuria remission at 12 months that can be used at baseline or after 3 or 6 months of treatment. Treatment exposures in the trials included supportive therapy, rituximab, calcineurin inhibitors, and cyclophosphamide. Predictors in the models included male sex and baseline and changes in serum albumin, proteinuria, and antibody levels, with or without changes in eGFR. Results Proteinuria remission at 12 months was achieved in 107 patients. Compared with the model at baseline, the 3-month and 6-month models had better model fit with lower Akaike information criterion (186/158 versus 225) and higher R 2 (52.7%/62.4% versus 25.8%), better discrimination with higher C-statistic (0.87 and 0.91 versus 0.75, P < 0.001), and better calibration with lower integrated calibration index (0.89%/2.22% versus 2.51%). The 3-month and 6-month models had no consistent difference in prediction performance, and decision curve analysis demonstrated similar net benefit for treatment decisions based on either model up to a threshold probability of 31%. Prediction performance was similar after internal validation using optimism correction. Prediction performance was maintained within subgroups of different treatment regimens, including supportive therapy, rituximab, calcineurin inhibitors, and cyclophosphamide. Conclusions Either the 3-month or 6-month models can be used in patients with antiphospholipase A2 receptor antibody associated membranous nephropathy after 3 or 6 months of treatment with a variety of immunosuppression or supportive therapy to predict remission status at 12 months.
Trajectory of Global Mental Health and Global Physical Health in Breast Cancer Survivorship
Pritzl, Stephanie L., Ruddy, Kathryn J. , Larson, Nicole L. , Ehlers, Shawna L. , Vierkant, Robert A. , Stan, Daniela , Olson, Janet E. , Couch, Fergus J. , Higgins, Alexandra

Mayo Clinic

Journal of the National Comprehensive Cancer Network | April 14, 2025 | Volume: 23 | Issue: 5 | Pages: 141-146

10.6004/jnccn.2024.7353 | PMID 40228538 Get It

Background: Breast cancer survivors face a risk of significant psychological distress, which can persist for years after their initial diagnosis. Although numerous guidelines and tools exist to help screen for and measure distress in patients with cancer, additional longitudinal studies are needed to better characterize the trajectory of distress over time. Patients and Methods: We conducted a longitudinal study to evaluate distress and health-related quality of life in patients with breast cancer. Annual assessments included global mental and physical health scores using the Patient-Reported Outcomes Measurement Information System Global-10 (PROMIS-10), posttraumatic stress symptoms using the Impact of Event Scale-Revised (IES-R), and depressive symptoms using the Patient Health Questionnaire-2 (PHQ-2). Eligible participants had stage 0–III breast cancer, with baseline surveys administered within 1 year of diagnosis. Annual follow-up surveys were conducted through year 4 after the baseline survey. Only patients who completed the baseline survey and at least one follow-up survey were included in this analysis. Individuals with stage IV or recurrent breast cancer were excluded. Results: A total of 2,140 individuals were included. Over time, global mental health scores declined slightly, with differences in T-scores from baseline ranging from 0.4 to 0.9. In contrast, global physical health scores improved, with differences in T-scores ranging from 0.3 to 0.6. Mean scores remained in the normative range. Depressive symptoms remained stable throughout the study period, while posttraumatic stress symptoms showed improvement over time. Conclusions: This study provides important longitudinal data on distress subtypes in breast cancer survivors with nonmetastatic disease. Although global mental health declined slightly, depression symptoms remained stable, and posttraumatic stress symptoms improved. Investigation of distress subtypes over time merits further study to advance detection of significant distress across the cancer continuum.
Comparative efficacy of levofloxacin, azithromycin, and doxycycline prophylaxis and treatment in an experimental Ureaplasma murine lung infection model
Al-Jabri, Maha Y. , Patel, Robin , Fleming, Derek , Patel, Robin , Fleming, Derek

Mayo Clinic

Antimicrobial Agents and Chemotherapy | April 14, 2025 | Volume: 69 | Issue: 5 | Pages: No page available

10.1128/aac.01724-24 | PMID 40227041 Get It

ABSTRACT Although lung transplant recipients who develop Ureaplasma- associated hyperammonemia syndrome are treated with Ureaplasma -targeted antibiotics, optimal therapy is incompletely defined, and typically not based on real-time antimicrobial susceptibility testing results. This study compared levofloxacin, azithromycin, and doxycycline prevention and treatment of Ureaplasma urealyticum (UU) and Ureaplasma parvum (UP) infections in an immunosuppressed murine lung infection model. For prophylaxis, mice received antibiotics before infection with UP-FS (susceptible to all study antibiotics), UP-AzmR (azithromycin-resistant), UP-LevR (levofloxacin-resistant), or UU-DoxR (doxycycline-resistant), with lung bacterial loads (color changing units [CCUs]) measured 18 hours following infection. For UP-FS, doxycycline was most active (Δ4.84 log 10 CCU/g; P = 0.0006), followed by levofloxacin (Δ2.45 log 10 CCU/g; P = 0.018), with azithromycin yielding a nonsignificant CCU reduction. Doxycycline (Δ1.9 log 10 CCU/g; P = 0.0025) and levofloxacin (Δ1.3 log 10 CCU/g; P = 0.004) showed activity against UP-AzmR. Only doxycycline showed activity against UP-LevR (Δ2.28 log 10 CCU/g; P = 0.0002), and only azithromycin showed activity against UU-DoxR (Δ0.67 log 10 CCU/g; P = 0.0175). For treatment, antibiotics were administered 24 hours following infection; doxycycline significantly reduced bacterial loads of all study isolates, except UU-DoxR. In addition, azithromycin was active against UP-LevR (Δ1.21 log 10 CCU/g reduction; P = 0.0003). In summary, except for doxycycline-resistant UU, doxycycline was active in preventing and treating Ureaplasma lung infection in immunosuppressed mice.
CMV Viremia and Colitis in Simultaneous Pancreas-Kidney Transplantation
Singh, Simardeep, Karatela, Shifa , Patel, Mipasha, Amin, Juhi , Gandhi, Devisha, Oring, Justin , Rajani, Aayushi J , Karatela, Shifa , Patel, Mipasha , Amin, Juhi V , Oring, Justin , Rajani, Aayushi J. , Patel, Mipasha, Gandhi, Devisha

Mayo Clinic

American Journal of Case Reports | April 14, 2025 | Volume: 26 | Issue: No issue available | Pages: No page available

10.12659/ajcr.946818 | PMID 40375543 Get It

p16, COX-2, and Ki67 Protein Expression in DCIS and Risk of Ipsilateral Invasive Breast Cancer
Rohan, Thomas E. , Zhang, Chenxin , Wang, Yihong , Couch, Fergus J. , Greenlee, Robert T. , Honda, Stacey , Stark, Azadeh , White, Larissa L. , Chitale, Dhananjay , Xue, Xiaonan , Ginsberg, Mindy , Loudig, Olivier , Wang, Yihong , Couch, Fergus J. , Chitale, Dhananjay A , Loudig, Olivier

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | April 14, 2025 | Volume: 34 | Issue: 6 | Pages: 1036-1039

10.1158/1055-9965.epi-25-0143 | PMID 40227115 Get It

Abstract Background: Prior research on the associations of p16, COX-2, and Ki67 immunopositivity in ductal carcinoma in situ (DCIS) tissue with the risk of subsequent ipsilateral invasive breast cancer (IBC) is limited. Methods: In a case–control study nested in a cohort of women diagnosed with DCIS, immunostaining for p16, COX-2, and Ki67 was performed on DCIS tissue from those who developed subsequent ipsilateral IBC (cases; n = 146) and on matched subjects who did not develop IBC (controls; n = 273). Conditional logistic regression was used to estimate ORs and 95% confidence intervals for the associations between immunopositivity for p16, COX-2, and Ki67 and the risk of subsequent ipsilateral IBC. Results: There was no association between p16, COX-2, and Ki67 immunopositivity, examined either individually or in combination, and a risk of ipsilateral IBC. Compared with all other groups, the multivariable OR (95% confidence interval) for women who were triple positive for the three markers was 1.16 (0.38–3.54). Conclusions: p16, COX-2, and Ki67 immunopositivity was not associated with altered risk of ipsilateral IBC in women with DCIS. Impact: p16, COX-2, and Ki67 may not be prognostic for ipsilateral IBC in women with DCIS.
The Risk of Type 2 Diabetes among Older Asian, Native Hawaiian, and Pacific Islander Colorectal Cancer Survivors: A Population-Based Study Using the SEER–Medicare Database
Liu, Kuang‐Yu , Chang, Chun-Pin E. , Lloyd, Shane , Tao, Randa , Nguyen, Timothy , Zhang, Zuo‐Feng , Hashibe, Mia, Liu, Kuangyu , Chang, Chun-Pin Esther , Hashibe, Mia , Lloyd, Shane L , Tao, Randa

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | April 14, 2025 | Volume: 34 | Issue: 6 | Pages: 998-1006

10.1158/1055-9965.epi-25-0037 | PMID 40227116 Get It

Abstract Background: Although colorectal cancer survival rates are improving, the risk of incident type 2 diabetes mellitus (T2D) among Asian, Native Hawaiian, and Pacific Islander (ANHPI) ethnic groups is poorly understood. This study aims to identify high-risk groups and quantify the risk across different periods. Methods: Using the SEER–Medicare database, colorectal cancer survivors who were ANHPI were matched to non-Hispanic White (NHW) survivors at a ratio of 1:3. Multivariable Cox regression models computed HRs and 95% confidence intervals (CI) for incident T2D. Results: The study included 6,463 NHW and 2,901 ANHPI colorectal cancer survivors diagnosed between 2000 and 2017. Among them, 715 NHW and 484 ANHPI developed T2D during 39,097 and 10,769 person-years of follow-up, respectively. ANHPI colorectal cancer survivors had an elevated T2D risk compared with NHW across all follow-up periods (HRoverall: 1.84, 95% CI, 1.51–2.25; HR1–5 years: 1.83, 95% CI, 1.45–2.30). Southeast and East Asians demonstrated the highest T2D risks. Colon cancer was linked to early postdiagnosis T2D risk, whereas rectal cancer was associated with later risk. No significant association was observed for Native Hawaiians and Pacific Islanders. Conclusions: ANHPI colorectal cancer survivors face a greater risk of T2D, particularly among Southeast and East Asians. These findings highlight the need for evidence-based survivorship strategies to prevent T2D and reduce ethnic disparities. Impact: This is the first study to examine T2D risk among ANHPI colorectal cancer survivors, providing critical insights to inform tailored diabetes prevention and survivorship care.
ELAINE 3: phase 3 study of lasofoxifene plus abemaciclib to treat ER+/HER2-, ESR1 -mutated, metastatic breast cancer
Bachelot, Thomas , Sammons, Sarah , Shen, Sherry , Twelves, Chris, Boruta, Gina, Portman, David, Sammons, Sarah L , Goetz, Matthew P. , Wander, Seth Andrew , Nonneville, Alexandre Tassin de , Gal‐Yam, Einav Nili , Damodaran, Senthil

Mayo Clinic

Future Oncology | April 13, 2025 | Volume: 21 | Issue: 11 | Pages: 1317-1324

10.1080/14796694.2025.2481825 | PMID 40222048 Get It

Bilateral External Ear Canal Duplication: A Case Report
Ebbert, Landon E. , Crockett, David J. , Page, Nathan , Ebbert, Joshua , Amoo-Quaye, Grace, Hanson, Nana Andoh Mensah, Appiah–Thompson, Peter , Crockett, David, Page, Nathan C , Crockett, David

Mayo Clinic

Ear, Nose & Throat Journal | April 12, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/01455613251333233 | PMID 40219830 Get It

Herein described is an eight-year-old female patient presenting with bilateral external ear canal duplication and a history of recurrent postauricular abscesses, otorrhea, and moderate left-sided conductive hearing loss. Previous incision and drainage of the postauricular abscesses yielded little long-term success. Medical history was otherwise unremarkable. Physical examination revealed a cystic mass in the right ear and postauricular fibrosis, likely a result of previous surgical interventions. An audiogram revealed asymmetric hearing function, with mild-to-moderate conductive hearing loss in the left ear contrasting normal hearing in the right ear, while tympanometry confirmed an intact right tympanic membrane but was precluded on the left due to purulent otorrhea. A head CT scan revealed postauricular soft tissue swelling and well-pneumatized mastoid air cells. Both ears were explored intraoperatively via postauricular incisions. Surgical excision included removal of a cyst, cartilaginous remnants, and fibrotic tissue. The patient was followed up to assess for postsurgical complications. The surgical site healed uneventfully; no new symptoms or recurrences of past symptoms of otorrhea, cyst formation, or abscesses had developed within the twelve weeks post-surgery. Although external ear canal duplications are rare, it is imperative that early, accurate diagnoses be made to ensure optimal patient outcomes.
Association of Body Mass Index in Late Life, and Change from Midlife to Late Life, With Incident Dementia in the ARIC Study Participants
Cannon, Ethan , Windham, B. Gwen , Griswold, Michael , Palta, Priya , Knopman, David S. , Sedaghat, Sanaz , Lutsey, Pamela L. , Knopman, David S. , Griswold, Michael , Cannon, Ethan J , Lutsey, Pamela L

Mayo Clinic

Neurology | April 11, 2025 | Volume: 104 | Issue: 9 | Pages: No page available

10.1212/wnl.0000000000213534 | PMID 40215425 Get It